Axios Pro Exclusive Content

Biotech deals of the week

21 hours ago

Venture Capital

T-Therapeutics, a U.K. developer of T-cell therapies for cancer and autoimmune diseases, raised $133m in Series B funding. Advent Life Sciences and British Business Bank led, joined by JJDC, Samsara BioCapital, M Ventures, Eli Lilly and insiders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF. Go deeper
Alethio Therapeutics, a U.K. developer of therapies for myeloproliferative neoplasms, raised $90m in Series A financing. Sofinnova Partners and RA Capital led, joined by Oxford Science Enterprises, Cancer Research Horizons, and the University of Oxford. Go deeper
Tolerance Bio, a Philadelphia-based immune biotech, is raising an $80m Series A. Go deeper
Anaheim Bio, a Dutch arthritis biotech, raised a €40m Series A from Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest, and Thuja Capital. Go deeper
Specific Biologics, a Toronto-based gene-editing therapies company, raised $35m in Series A funding led by Hatteras Venture Partners. Lumira Ventures and adMare BioInnovations, Genesys Capital, Business Development Bank of Canada's (BDC) Life Sciences Venture Fund, DeepWork Capital and Seido Capital joined. Go deeper

nPhase, an Atlantic Beach, Fla.-based clinical data platform, raised $30m in Series D funding led by Viking Global Investors. Go deeper
Thryv Therapeutics, an SF-based heart failure biotech, raised $30m in Series B funding. InClin led, joined by Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund, and Alexandria Venture Investments. Go deeper
Bit.bio, a British synthetic biology platform, raised $25m in Series D funding from M&G Investments and Abcam founder Jonathan Milner. Go deeper
Biograil, a Copenhagen-based therapeutic oral device developer, raised €20m from Verve Ventures and Megatrend Invest. Go deeper
Vitroscope, a Norwegian live-tissue platform, raised $7m in seed funding. Cerberus Ventures and YZR Capital led, joined by Arcas Ventures, Golden Egg Check, and Devico Invest. Go deeper

Cinven agreed to buy Theramex, a London-based pharma company focused on women's health, from PAI Partners and Carlyle for €2.6b. Go deeper
GrowthCurve Capital acquired a majority stake in TailorMed, a medication access, affordability, and adherence platform. Go deeper

Rezera, a Boston-based biotech focused on inflammatory diseases, set IPO terms to 16.7m shares at $11-$13. It would have a $254m fully diluted valuation at the midpoint, and plans to list on the Nasdaq (RZRA). The Phase 3 biotech has raised $150m from firms like Novo Holdings, Blue Owl, 5AM Ventures, F-Prime, Epidarex Capital, and Sofinnova Capital. Go deeper

AstraZeneca (NYSE: AZN) last month offered to buy Rhythm Pharmaceuticals (Nasdaq: RYTM) for around $10b, or $124 per share, per multiple reports. Go deeper

Karyopharm Therapeutics, a Newton, Mass.-based blood cancer biotech, filed for Chapter 11 bankruptcy and plans to merge with Ayrmid, the parent company of Naples, Fla.-based hematology biotech Gamid Cell. Go deeper
Lonza (Swiss: LONN) agreed to acquire five CDMO manufacturing sites in the U.S. from Merck KGaA. Go deeper

Biograil, a Copenhagen-based therapeutic oral device developer, raised €20m from Verve Ventures and Megatrend Invest. Go deeper
Evommune, a Palo Alto, Calif.-based inflammatory disease biotech, will pay $30m upfront and up to $1.1b to Chinese drugmaker Hinova Pharmaceuticals to in-license a molecular glue degrader. Go deeper

Yosemite, an oncology-focused VC firm led by Reed Jobs, raised $350m for its second fund. Go deeper

Andrew Glass, former Vivasure Medical CEO, joined Netherlands-based immune biotech Trained Therapeutix Discovery as CEO. Go deeper
Cecile Guegan was named CFO at Pfizer (NYSE: PFE) after serving in the role on an interim basis since August. Go deeper
Damon Daulerio, former senior director of regulatory affairs at Insmed Incorporated, joined Nanoscope Therapeutics as executive director of regulatory affairs. Go deeper
Dan Janiak, AstraZeneca's former exec director of business development, was named chief business officer at Rockville, Md.-based cancer and immune biotech OncoC4. Go deeper
Dean Hakanson, former head of U.S. medical affairs at Gilead, joined West Palm Beach, Fla.-based GOA Therapeutics as chief medical officer. Go deeper